Products for Research Use Only
RegisterLogin

Oxaprozin

CAT: 0804-HY-B0808-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0808-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
CAS Number
21256-18-8
Product Name Alternative
Oxaprozinum; Wy21743
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; Apoptosis; COX; IKK; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Oxaprozin.html
Purity
99.94
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1
Molecular Formula
C18H15NO3
Molecular Weight
293.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-1; COX-2; IKK; NF-κB

Alternative Products

CatalogName
018865Oxaprozin

Popular Products